Literature DB >> 10971819

How can the cellular immune response control hepatitis B virus replication?

M K Maini1, A Bertoletti.   

Abstract

In this review we focus on aspects of the virus-specific cellular immune response, although we should point out that all the components of the innate and adaptive immune response are likely to play a role in successful control of hepatitis B virus (HBV) infection. We concentrate particularly on the relevance of the polyclonality and multispecificity of the HBV-specific cytotoxic T cell response to its antiviral activity. In this context, we discuss the possible role of viral escape mutations and highlight evidence from other models of the benefit of multispecificity in antiviral responses. We stress the contribution of CD4 help for effective CD8 responses and raise the possibility that HBV may produce factors inhibiting the antiviral response.

Entities:  

Mesh:

Year:  2000        PMID: 10971819     DOI: 10.1046/j.1365-2893.2000.00234.x

Source DB:  PubMed          Journal:  J Viral Hepat        ISSN: 1352-0504            Impact factor:   3.728


  10 in total

1.  Sustained and transient oscillations and chaos induced by delayed antiviral immune response in an immunosuppressive infection model.

Authors:  Hongying Shu; Lin Wang; James Watmough
Journal:  J Math Biol       Date:  2013-01-11       Impact factor: 2.259

2.  Different hepatitis B virus core gene mutations in children with chronic infection and hepatocellular carcinoma.

Authors:  Y-H Ni; M-H Chang; H-Y Hsu; D-J Tsuei
Journal:  Gut       Date:  2003-01       Impact factor: 23.059

3.  Immunomodulation therapy in children with chronic hepatitis B.

Authors:  Murat Karaoglan; Fikret Demirci; Yavuz Coskun; Ilkay Karaoglan; Ziya Bayraktaroglu; Vahap Okan; Tekin Karsligil
Journal:  J Natl Med Assoc       Date:  2006-02       Impact factor: 1.798

4.  Reduced hepatitis B virus (HBV)-specific CD4+ T-cell responses in human immunodeficiency virus type 1-HBV-coinfected individuals receiving HBV-active antiretroviral therapy.

Authors:  J Judy Chang; Fiona Wightman; Angeline Bartholomeusz; Anna Ayres; Stephen J Kent; Joseph Sasadeusz; Sharon R Lewin
Journal:  J Virol       Date:  2005-03       Impact factor: 5.103

Review 5.  Clinical impact of hepatitis B and C virus envelope glycoproteins.

Authors:  Hélène Jeulin; Aurélie Velay; John Murray; Evelyne Schvoerer
Journal:  World J Gastroenterol       Date:  2013-02-07       Impact factor: 5.742

6.  Boosting immunity by antiviral drug therapy: a simple relationship among timing, efficacy, and success.

Authors:  Natalia L Komarova; Eleanor Barnes; Paul Klenerman; Dominik Wodarz
Journal:  Proc Natl Acad Sci U S A       Date:  2003-02-06       Impact factor: 11.205

7.  Generation of cytotoxic T cell against HBcAg using retrovirally transduced dendritic cells.

Authors:  Chuan-Lin Ding; Kun Yao; Tian-Tai Zhang; Feng Zhou; Lin Xu; Jiang-Ying Xu
Journal:  World J Gastroenterol       Date:  2003-07       Impact factor: 5.742

8.  Association of markers of chronic viral hepatitis and blood mercury levels in US reproductive-age women from NHANES 2001-2008: a cross-sectional study.

Authors:  Mary C Sheehan; Thomas A Burke; Patrick N Breysse; Ana Navas-Acien; John McGready; Mary A Fox
Journal:  Environ Health       Date:  2012-09-12       Impact factor: 5.984

9.  Variability and conservation in hepatitis B virus core protein.

Authors:  Benjamin M Chain; Richard Myers
Journal:  BMC Microbiol       Date:  2005-05-27       Impact factor: 3.605

10.  Polymorphisms in CISH gene are associated with persistent hepatitis B virus infection in Han Chinese population.

Authors:  Zhangyong Hu; Jinliang Yang; Yangping Wu; Guolian Xiong; Yali Wang; Jun Yang; Lan Deng
Journal:  PLoS One       Date:  2014-06-25       Impact factor: 3.240

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.